Dr. Sushant Kamath is currently, Manager - Risk Assessment in the Global Preclinical & Product Safety division of Abbott Healthcare Pvt Ltd., where he is involved in toxicological risk assessment of Abbott's product portfolio. He is responsible for scientific delivery and strategic development of Nonclinical Safety studies/bridging studies for generics and fixed-dose combinations for registrations in regulated and non-regulated markets. Further, he is involved in In Silico assessment of impurities in API and finished products through QSAR and Read-Across approaches.
Dr Kamath earned his PhD in Toxicology from SASTRA University working on a project funded by the Department of Science & Technology (DST), Goverment of India. He has worked on risk assessment of metal-based traditional medicines and carried out preclinical toxicity studies to understand systemic as well genetic toxicity of metal-based traditional drugs.
Prior to joining Abbott, Dr. Kamath worked in different domains like BA/BE studies and in In Vitro DMPK.
Dr. Kamath's long term goal is to work towards establishing New Approach Methods (NAMs) and In Silico based models in line with the 3Rs principles for animal free testing of drug products.